Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results
Fiorenza De Rose
◽
Antonella Fogliata
◽
Davide Franceschini
◽
Piera Navarria
◽
Elisa Villa
◽
...
D. Azria
◽
M. Ozsahin
◽
G. Romieu
◽
S. Gourgou
◽
M. Gutowski
◽
...
2008 ◽
Vol 72
(1)
◽
pp. S92-S93
◽
D. Azria
◽
G. Romieu
◽
Y. Belkacemi
◽
K. Zaman
◽
S. Gourgou
◽
...
2018 ◽
Vol 18
(6)
◽
pp. 474-480
◽
Takashi Kuwayama
◽
Seigo Nakamura
◽
Naoki Hayashi
◽
Toshimi Takano
◽
Koichiro Tsugawa
◽
...
Liulu Zhang
◽
Zhi‐Yong Wu
◽
Jie Li
◽
Ying Lin
◽
Zhenzhen Liu
◽
...
S. Jones
◽
S. Jones
◽
R. Collea
◽
R. Collea
◽
R. Oratz
◽
...
JG Bazan
◽
J Stephens
◽
A Terando
◽
R Skoracki
◽
S McElroy
◽
...
2008 ◽
Vol 72
(1)
◽
pp. S152
◽
C. Lemanski
◽
D. Azria
◽
N. Aillères
◽
S. Gourgou
◽
L. Santoro
◽
...
2010 ◽
Vol 77
(4)
◽
pp. 1289
Jayant S. Vaidya
◽
Jeffrey S. Tobias
◽
Michael Baum
◽
Mohammed Keshtgar
◽
Norman Williams
◽
...
S Jones
◽
R Collea
◽
D Paul
◽
R Oratz
◽
S Sedlacek
◽
...
S Jones
◽
R Collea
◽
D Paul
◽
S Sedlacek
◽
A Favret
◽
...